针对局部晚期或转移性尿路上皮癌,在维持阿维单抗或派姆单抗后再用铂基化疗或强制使用维多汀。

IF 1.2 4区 医学 Q4 ONCOLOGY
Bladder Cancer Pub Date : 2025-03-20 eCollection Date: 2025-01-01 DOI:10.1177/23523735251317423
Nobutaka Nishimura, Makito Miyake, Norimi Takamatsu, Kosuke Mieda, Kuniaki Inoue, Akira Tachibana, Keichi Sakamoto, Mikiko Onishi, Fumisato Maesaka, Takanosuke Yoshikawa, Mitsuru Tomizawa, Takuto Shimizu, Kenta Onishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Nobumichi Tanaka, Kiyohide Fujimoto
{"title":"针对局部晚期或转移性尿路上皮癌,在维持阿维单抗或派姆单抗后再用铂基化疗或强制使用维多汀。","authors":"Nobutaka Nishimura, Makito Miyake, Norimi Takamatsu, Kosuke Mieda, Kuniaki Inoue, Akira Tachibana, Keichi Sakamoto, Mikiko Onishi, Fumisato Maesaka, Takanosuke Yoshikawa, Mitsuru Tomizawa, Takuto Shimizu, Kenta Onishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Nobumichi Tanaka, Kiyohide Fujimoto","doi":"10.1177/23523735251317423","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In current clinical practice, the use of switch maintenance avelumab is recommended for patients with locally advanced and metastatic urothelial carcinoma who experience favorable responses to first-line chemotherapy.</p><p><strong>Objective: </strong>We aimed to evaluate the potential advantages of platinum-based chemotherapy (Pl-CT) rechallenge after maintenance avelumab.</p><p><strong>Methods: </strong>A retrospective analysis involving 383 patients treated with first-line Pl-CT between 2015 and 2023 was conducted. Subsequent treatment strategies included Pl-CT or enfortumab vedotin (EV) following maintenance avelumab or pembrolizumab, and their benefit was evaluated.</p><p><strong>Results: </strong>Pl-CT rechallenge following maintenance avelumab did not show significant benefits, demonstrating lower response rates and shorter progression-free survival compared to EV. Conversely, both Pl-CT and EV following pembrolizumab showed similar efficacy.</p><p><strong>Conclusions: </strong>These findings suggest that in the current clinical landscape, EV might be a more preferable option than Pl-CT rechallenge subsequent to avelumab maintenance therapy, thereby influencing treatment decisions for metastatic urothelial carcinoma.</p>","PeriodicalId":54217,"journal":{"name":"Bladder Cancer","volume":"11 1","pages":"23523735251317423"},"PeriodicalIF":1.2000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926830/pdf/","citationCount":"0","resultStr":"{\"title\":\"Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma.\",\"authors\":\"Nobutaka Nishimura, Makito Miyake, Norimi Takamatsu, Kosuke Mieda, Kuniaki Inoue, Akira Tachibana, Keichi Sakamoto, Mikiko Onishi, Fumisato Maesaka, Takanosuke Yoshikawa, Mitsuru Tomizawa, Takuto Shimizu, Kenta Onishi, Shunta Hori, Yosuke Morizawa, Daisuke Gotoh, Yasushi Nakai, Nobumichi Tanaka, Kiyohide Fujimoto\",\"doi\":\"10.1177/23523735251317423\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In current clinical practice, the use of switch maintenance avelumab is recommended for patients with locally advanced and metastatic urothelial carcinoma who experience favorable responses to first-line chemotherapy.</p><p><strong>Objective: </strong>We aimed to evaluate the potential advantages of platinum-based chemotherapy (Pl-CT) rechallenge after maintenance avelumab.</p><p><strong>Methods: </strong>A retrospective analysis involving 383 patients treated with first-line Pl-CT between 2015 and 2023 was conducted. Subsequent treatment strategies included Pl-CT or enfortumab vedotin (EV) following maintenance avelumab or pembrolizumab, and their benefit was evaluated.</p><p><strong>Results: </strong>Pl-CT rechallenge following maintenance avelumab did not show significant benefits, demonstrating lower response rates and shorter progression-free survival compared to EV. Conversely, both Pl-CT and EV following pembrolizumab showed similar efficacy.</p><p><strong>Conclusions: </strong>These findings suggest that in the current clinical landscape, EV might be a more preferable option than Pl-CT rechallenge subsequent to avelumab maintenance therapy, thereby influencing treatment decisions for metastatic urothelial carcinoma.</p>\",\"PeriodicalId\":54217,\"journal\":{\"name\":\"Bladder Cancer\",\"volume\":\"11 1\",\"pages\":\"23523735251317423\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11926830/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bladder Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/23523735251317423\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bladder Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/23523735251317423","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:在目前的临床实践中,对于对一线化疗反应良好的局部晚期和转移性尿路上皮癌患者,推荐使用切换维持性avelumab。目的:我们旨在评估维持阿韦单抗后铂基化疗(Pl-CT)再挑战的潜在优势。方法:回顾性分析2015 - 2023年间383例接受一线Pl-CT治疗的患者。随后的治疗策略包括在维持avelumab或pembrolizumab后使用plt - ct或enfortumab vedotin (EV),并评估其益处。结果:与EV相比,维持avelumab后的Pl-CT再挑战没有显示出显着的益处,显示出更低的缓解率和更短的无进展生存期。相反,pembrolizumab治疗后的Pl-CT和EV均显示出相似的疗效。结论:这些研究结果表明,在目前的临床情况下,在avelumab维持治疗后,EV可能是比Pl-CT再挑战更可取的选择,从而影响转移性尿路上皮癌的治疗决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma.

Background: In current clinical practice, the use of switch maintenance avelumab is recommended for patients with locally advanced and metastatic urothelial carcinoma who experience favorable responses to first-line chemotherapy.

Objective: We aimed to evaluate the potential advantages of platinum-based chemotherapy (Pl-CT) rechallenge after maintenance avelumab.

Methods: A retrospective analysis involving 383 patients treated with first-line Pl-CT between 2015 and 2023 was conducted. Subsequent treatment strategies included Pl-CT or enfortumab vedotin (EV) following maintenance avelumab or pembrolizumab, and their benefit was evaluated.

Results: Pl-CT rechallenge following maintenance avelumab did not show significant benefits, demonstrating lower response rates and shorter progression-free survival compared to EV. Conversely, both Pl-CT and EV following pembrolizumab showed similar efficacy.

Conclusions: These findings suggest that in the current clinical landscape, EV might be a more preferable option than Pl-CT rechallenge subsequent to avelumab maintenance therapy, thereby influencing treatment decisions for metastatic urothelial carcinoma.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Bladder Cancer
Bladder Cancer Medicine-Urology
CiteScore
1.60
自引率
0.00%
发文量
35
期刊介绍: Bladder Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pharmacology, ethics, patient advocacy and survivorship, diagnosis and treatment of tumors of the bladder and upper urinary tract. The journal publishes research reports, reviews, short communications, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research in basic science, translational research and clinical medicine that expedites our fundamental understanding and improves treatment of tumors of the bladder and upper urinary tract.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信